(NUVB) – StreetInsider.com Reports
-
Nuvation Bio Inc (NUVB) PT Raised to $5 at RBC Capital
-
Nuvation Bio (NUVB) Appoints Colleen Sjogren as Chief Commercial Officer
-
Nuvation Bio Inc (NUVB) PT Raised to $8 at H.C. Wainwright on AnHeart deal
-
Jefferies Upgrades Nuvation Bio Inc (NUVB) to Buy
-
BTIG Upgrades Nuvation Bio Inc (NUVB) to Buy, has 'two potentially best-in-class drugs'
-
Nuvation Bio (NUVB) to Acquire AnHeart Therapeutics in All-Stock Deal
-
Nuvation Bio Inc (NUVB) PT Raised to $5 at H.C. Wainwright
-
Nuvation Bio Inc. (NUVB) Tops Q4 EPS by 4c
-
Nuvation Bio (NUVB) Appoints Robert Mashal to its Board
-
Nuvation Bio (NUVB) Announces FDA Clearance of IND Application for NUV-1511
-
Nuvation Bio (NUVB) Announces Resignation of Oleg Nodelman from Board
-
Nuvation Bio (NUVB) Announces Departure of Chief Financial Officer
-
Nuvation Bio Inc (NUVB) PT Lowered to $4 at RBC Capital
-
Nuvation Bio Inc. (NUVB) Tops Q3 EPS by 2c
-
Nuvation Bio Inc. (NUVB) Tops Q2 EPS by 2c
-
Einhorn's Greenlight Capital enters Black Knight (BKI), New York Community Bancorp (NYB), more - 13F
-
Nuvation Bio Inc (NUVB) PT Lowered to $5 at RBC Capital
-
Jefferies Downgrades Nuvation Bio Inc (NUVB) to Hold
-
Nuvation Bio Inc (NUVB) PT Lowered to $6 at RBC Capital
-
BTIG Downgrades Nuvation Bio Inc (NUVB) to Neutral
-
UPDATE: BMO Capital Downgrades Nuvation Bio Inc (NUVB) to Market Perform
-
Nuvation Bio (NUVB) Announces Discontinuation of NUV-422 Clinical Development Program
-
Nuvation Bio (NUVB) Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors
-
Nuvation Bio Inc (NUVB) PT Lowered to $14 at RBC Capital
-
H.C. Wainwright Starts Nuvation Bio Inc (NUVB) at Buy
-
Nuvation Bio Inc (NUVB) PT Lowered to $12 at BMO Capital on Lower Assumed Penetration Rates, but Optimistic Reiterated Ahead of Phase 1 NUV-422 Readout
-
Nuvation Bio Inc (NUVB) PT Lowered to $12 at BMO Capital on Reduced Breast Cancer Assumptions
-
Nuvation Bio (NUVB) Announces FDA Clearance of Investigational New Drug Application for NUV-868 for the Treatment of Advanced Solid Tumors
-
Nuvation Bio (NUVB) Granted FDA Fast Track Designation for NUV-422 for the Treatment of High-Grade Gliomas, Including Glioblastoma Multiforme
-
Nuvation Bio (NUVB) Granted FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Prostate Cancer
-
Nuvation Bio (NUVB) Announces FDA Clearance of IND for NUV-422 for the Treatment of Advanced Breast Cancer
-
BTIG Assumes Nuvation Bio Inc (NUVB) at Buy
-
Nuvation Bio Inc (NUVB) PT Raised to $21 at Wedbush, Following Earnings
-
Nuvation Bio Inc (NUVB) Notes From Management Meetings - Jefferies
-
RBC Capital Starts Nuvation Bio Inc (NUVB) at Outperform
-
BTIG Reiterates Buy Rating on Nuvation Bio Inc (NUVB) After Earnings
-
Nuvation Bio (NUVB) Granted Orphan Drug Designation for NUV-422 for the Treatment of Patients with Malignant Gliomas
-
UPDATE: Jefferies Starts Nuvation Bio Inc (NUVB) at Buy
-
Wedbush Starts Nuvation Bio Inc (NUVB) at Outperform
-
Cowen Starts Nuvation Bio Inc (NUVB) at Outperform
-
UPDATE: BMO Capital Starts Nuvation Bio Inc (NUVB) at Outperform
Back to NUVB Stock Lookup